CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 2,831 enrolled
Drug / intervention
Betamethasone +1 moredrug
Likely dose
Betamethasone 3 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01222247
NCT01222247Phase 3Completed

Antenatal Late Preterm Steroids (ALPS): A Randomized Placebo-Controlled Trial

The George Washington University Biostatistics Center·interventional·Posted Oct 18, 2010·Updated Mar 28, 2023

In Brief

A Phase 3 clinical trial evaluating Betamethasone and Placebo for Pregnancy and 3 related conditions. Completed, enrolled 2,831 participants across 17 sites.

Detailed Summary

This is a randomized placebo controlled trial to evaluate whether antenatal corticosteroids can decrease the rate of neonatal respiratory support, thus decreasing the rate of NICU admissions and improving short-term outcomes in the late preterm infant. The use of antenatal corticosteroids has been shown to be beneficial in women at risk for preterm delivery prior to 34 weeks but has not been evaluated in those likely to deliver in the late preterm period

Study Details

Timeline

Phase 3CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedOct 18, 2010
Enrollment StartOct 1, 2010
Primary CompletionMar 1, 2015
Study CompletionAug 31, 2022
TodayJul 2, 2026
Enrollment to primary: 4.4 yearsPosted 15.7 years ago

Interventions

Betamethasonedrug

The active study drug, betamethasone. 3 mg per ml betamethasone sodium phosphate 3 mg per milliliter betamethasone acetate The first dose of study drug medication will be administered at randomization as 2 ml injection; the next dose of 2 ml will be administered 24 hours later.

Placebodrug

Similar course of identical appearing placebo: 2 mL IM injections, 24 hours apart.